Beaufort's note published this morning on Research Tree... "Following Horizon's announcement on 12th of May of a deal with an NGS Company, we are now given the name of the Company - QIAGEN N.V. a US$5bn NASDAQ and Frankfurt listed global leading NGS platform enterprise. Importantly, the deal demonstrates the impact Horizon's Reference Standards are having in supporting the rapidly growing NGS market. Further, future joint collaborations are expected as work continues to unlock the full clinical and research potential of both technologies. In addition, QIAGEN's GeneRead QIAact Actionable Insights Tumor Panel is the first in a family of multiplex panels for the GeneReader NGS System targeting the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma. The accuracy, consistency and reliability of this Panel was validated through extensive testing compared with the control data derived from Horizon's Reference Standards, proving its performance. Yesterday's announcement validates further the quality of the Horizon Discovery's services on offer. We believe there is more opportunities for Horizon Discovery in this space. We..."
Welcome to the new Horizon Discovery Group stream forum! Messages posted in the Horizon Discovery Group stream will be logged here for posterity.
Latest from the Community...
Latest from the Community...
Latest from the Community...